For this week’s Article of the Week, we look at an article that describes a review of patient data from the Mayo Clinic. The study sought to identify factors that could guide re-treatment in AL amyloidosis, with the goal of preventing organ progression. Covering a period 1996-2014, the timeframe necessarily included a range of treatment approaches. Nevertheless, in this cohort, relapse/progression status prior to institution of second-line therapy could predict outcomes. Additionally, organ progression could occur in the absence of evidence of haematologic progression.